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ABSTRACT 
 
Three groups of Shami goats were randomly vaccinated with Brucevac (Rev. 1) vaccine. Group 1 was 
vaccinated subcutaneously with a full dose (1.54 x 10
9 organisms). Group 2 was vaccinated conjunctively 
with one eye drop (5.2 x 10
8 organisms), while Group 3 was injected subcutaneously with a reduced dose 
(7.1 x 10
5 organisms) of vaccine. Blood samples were collected before vaccination, two, four, eight, 15 and 
24 weeks post vaccination. All samples were tested through CFT, ELISA, SAT and Rose Bengal plate test. 
All serological tests used detected a higher percentage of vaccinated female kids with a full dose than they did 
in other groups vaccinated with a reduced dose or with a conjunctival dose of Rev.1 vaccine. The overall 
results suggested that 100% of animals vaccinated with a conjunctival dose became positive to CFT at two, 
four, eight and 15 weeks post vaccination, and then the percentage of seropositive animals declined and 
became 20% at 24 weeks post inoculation. The conjunctival route of vaccination significantly reduced the 
intensity and duration of the post vaccination serological response, which makes the use of this vaccine 
compatible with brucellosis programmes, even when these are based on a test-and–slaughter policy. The 
overall results showed that Shami goats responded to Rev.1 vaccine in the expected way. The majority of 
animals were seropositive to the CFT by two weeks after vaccination with higher numbers of seropositive 
animals in the kids group vaccinated with a full dose of Rev.1 vaccine.  
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INTRODUCTION 
 
Brucellosis is an important infectious disease of 
sheep and goats and is considered to be the most serious 
zoonotic disease for humans (Gul and Khan, 2007). B. 
melitensis is primarily responsible for brucellosis in 
sheep and goats (Enright, 1990). Brucellosis occurs in 
small ruminants in the Mediterranean and Middle 
Eastern countries, particularly Iran, and spreads 
eastward to southern regions of Russia, Mongolia and 
northern China (Castrucci and Cilli, 1991).  
The majority of abortions in sheep and goats 
occurred in the last month of gestation. Infectious 
diseases such as brucellosis, campylobacteriosis, 
toxoplasmosis, chlamydiosis and Q fever usually cause 
abortion in late gestation, therefore, special attention 
should be paid towards looking for them. They can be of 
considerable economic importance to the sheep and goat 
industry (Aldomy et al., 2009). 
The serological tests commonly used for the 
diagnosis of B. melitensis infection are the Rose Bengal 
Plate test (RBPT), SAT and CFT (Alton, 1990). 
Recently, the ELISA has been employed for the 
diagnosis of brucellosis. Control measures are based on 
strict hygiene and vaccination of susceptible animals 
like sheep and goats.  Vaccination is regarded as a 
measure for reducing the prevalence of the disease 
eventually to a level where eradication by test and 
slaughter can be considered. Of the vaccines now used 
for immunizing small ruminants against B. melitensis, 
Rev.1 vaccine is generally preferred (FAO/WHO, 1986; 
OIE, 2004).  
The Rev.1 vaccine is indicated to protect small 
ruminants against brucellosis and to protect females 
from abortion in regions where the disease occurs. 
Conjunctival vaccination is safer than subcutaneous 
vaccination but is not safe enough to be applied 
regardless of pregnancy status of animals (Blasco, 
1997) and the duration of immunity conferred by this 
method of vaccination is the subject of controversy. 
This study was carried out to demonstrate the immune 
responses of kids and adult goats to Brucevac vaccine 
(full dose, reduced dose and conjunctival dose) by the 
use of the CFT, ELISA, SAT and Rose Bengal plate 
test.  
 
MATERIALS AND METHODS 
 
General procedure and origin of specimens 
This study was conducted from November 2005 to 
May 2006 at a well-managed, feedlot operation in 
Alwala Goats Farm (Ministry of Agriculture Shami 
Goats' Station), Amman, Jordan. Experimental animals 
were sound and apparently healthy and were randomly Pakistan Vet. J., 2009, 29(4): 149-153.   150
selected from a known source obtained from brucellosis 
free stocks and reared in isolation.  
Three groups of ear tagged goats were selected 
randomly. Group 1 consisted of six female kids aged 
between 3 and 5 months, Group 2 consisted of eight 
female goats aged between 9 and 11 months and Group 
3 contained 10 male goats aged 12-18 months. All 
animals were provided with adequate housing and kept 
under conditions in which they would remain healthy, 
would not be subjected to cross-infection, and should 
not be overcrowded. They were provided with good 
hygienic conditions, a balanced diet and abundant 
supply of water.  
  
Vaccination 
All animals were bled before vaccination and then 
were inoculated with Rev.1 vaccine prepared by the 
Jordan Bio-Industries Centre (JOVAC), Aman, Jordan. 
Each animal in Group 1 was vaccinated subcutaneously 
with a full dose (1.54 x 10
9 viable organisms, Batch No. 
BR 01016-01) of the Brucevac (Rev.1) vaccine; each 
animal in Group 2 was vaccinated conjunctively with 
one eye drop (5.2 x 10
8 viable organisms, Batch No. 
BR 5905-01) of the Brucevac (Rev.1) vaccine and each 
animal in Group 3 was injected subcutaneously with a 
reduced dose (7.1 x 10
5 viable organisms, Batch No. 
BR 4805-02) of Brucevac (Rev.1) vaccine. Blood 
samples were taken from animals of all groups before 
vaccination and then at 2, 4, 8, 15 and 24 weeks post 
vaccination for serum collection. All serum samples 
collected from the experimental animals were subjected 
to Rose Bengal Plate test (RBPT), CFT, SAT and 
ELISA. 
 
Complement fixation test (CFT) 
The hot CFT method for Brucella melitensis was 
used, as described by Alton et al. (1988). The CFT kit 
produced by the JOVAC, Amman, Jordan was used. As 
a general rule, the minimum positive titre of vaccinated 
animals is double the minimum positive titre of non-
vaccinated animals (Staak, 1990). However, sera 
completely inhibiting lysis at a dilution of 1 in 10 were 
considered positive, partial lysis was taken as doubtful 
and complete lysis was regarded as negative at this 
dilution (Cox et al., 1977). 
 
Rose Bengal Plate test 
Serum samples and Brucella antigen stained with 
Rose Bengal produced by JOVAC,  Amman Jordan 
were brought to room temperature before testing. One 
drop (30 µl) of undiluted test serum was placed on a 
white plate and one drop (30 µl) of the antigen was 
placed beside it. Antigen and serum were mixed 
thoroughly with a disposable wooden stick and then the 
test plate was moved vigorously in a wide circle, five to 
six times clockwise, followed by five to six times 
anticlockwise. The plate was examined after four 
minutes. Any degree of agglutination was considered to 
be positive. 
 
Serum agglutination test (SAT) 
The test was based on the Wright-test produced by 
JOVAC, Amman Jordan. SAT titers ≥1:40 were 
indicative of Brucella antibodies. 
 
ELISA 
An indirect ELISA kit produced by JOVAC, 
Amman Jordan
  was used. Test result was generated 
through the following equation: 
Percentage positivity (%p) =absorbance (test sample) 
 
OD of sample - OD of negative control  
-------------------------------------------------------------------X 100 
OD of strong positive control - OD of negative control 
OD= optical density. 
Strong positive control antibody lies between >60-100. 
Moderate positive control antibody lies between >31-59 
and negative control antibody lies between 0-30. 
           
RESULTS 
 
In the present study, all animals which were bled 
before vaccination were negative for brucellosis. No 
significant local or systemic reaction was observed during 
the first three weeks of the study period. 
 
Female kids vaccinated with a full dose  
In six female kids vaccinated with live attenuated full 
dose (1.54 x 10
9 CFU) of Brucevac (Rev 1) vaccine, peak 
mean CFT titre (1:107) was observed two weeks, whereas 
peak mean SAT titre (1:96) was observed 15 weeks post 
vaccination. The titres then declined to 1:85, 1:36, 1:16 
and 1:8 for the CFT at four, eight, 15 and 24 weeks post 
vaccination, whereas the titre of 1:80 was demonstrated 
eight and 24 weeks post vaccination for the SAT (Table 
1).  
 
Table 1: Mean CFT and SAT titres in female kids 
vaccinated with a full dose of Brucevac 
(Rev.1) live attenuated B. melitensis vaccine 
Weeks post 
vaccination 
CFT  
titres 
SAT  
titres 
0 1:0  1:0 
2 1:107  1:37 
4 1:85  1:70 
8 1:36  1:80 
15 1:16  1:96 
24 1:8  1:80 
 
The serological results also indicated that CFT 
detected antibodies to Brucella in 100, 100, 100, 100 and 
50% of animals two, four, eight, 15, and 24 weeks after 
vaccination, respectively compared to 100, 100, 100, 100, 
100%, for the ELISA and the RBPT. The SAT detected Pakistan Vet. J., 2009, 29(4): 149-153.   151
the lowest percentages (83%) two weeks after vaccination 
but detected 100% four, eight, 15 and 24 weeks post 
vaccination, respectively. The RBPT and the ELISA test 
gave similar results in this group. 
 
Goats vaccinated with a conjunctival dose  
For adult female goats vaccinated with live 
attenuated conjunctival dose (5.2 x 10
8 organisms) of 
Brucevac (Rev.1) vaccine, peak mean CFT and SAT 
titres (1:87 and 1:120, respectively) were observed four 
weeks post vaccination. They then declined to 1:67, 1:32 
and 1:6 for the CFT and 1:72, 1:24 and 1:14 for the SAT 
at eight, 15 and 24 weeks post vaccination, respectively 
(Table 2).  
 
Table 2: Mean CFT and SAT titres in female goats 
vaccinated with a conjunctival dose of 
Brucevac (Rev.1) B. melitensis vaccine 
Weeks post  
vaccination 
CFT 
titres 
SAT 
titres 
0 1:0  1:0 
2 1:63  1:33 
4 1:87  1:120 
8 1:67  1:  72 
15 1:32  1:24 
24 1:6  1:14 
 
The serological test results indicated that CFT 
detected antibodies to Brucella in 100, 100, 100, 100 and 
20% of animals two, four, eight, 15, and 24 weeks after 
vaccination compared to 100, 100, 100, 100 and 100%, in 
the ELISA and the RBPT. Only 20% animals vaccinated 
with the conjunctival dose gave positive titre to CFT 
(1:10) 6 months post vaccination i.e. nearly sera of all 
vaccinated animals were negative to CFT 24 weeks after 
vaccination. 
The SAT detected 63% of animals two weeks post 
vaccination and detected the lowest percentages (20 and 
0%) 15 and 24 weeks post vaccination. The RBPT and 
the ELISA gave similar results in this group. 
 
Male goats vaccinated with a reduced dose  
In male goats vaccinated with live attenuated reduced 
dose (7.1 x 10
5 CFU) of Brucevac (Rev.1) vaccine; peak 
mean CFT and SAT titres (1:38 and 1:68, respectively) 
were observed two weeks after vaccination. They then 
declined to 1:16, 1:11, 1:5 and 1:3 for the CFT and 1:33, 
1:7, 1:0 and 1:0 for the SAT at 4, 8, 15 and 24 weeks post 
vaccination, respectively (Table 3).  
 
Table 3: Mean CFT and SAT titres in bucks 
vaccinated with a reduced dose of 
Brucella melitensis Rev.1 vaccine 
Weeks post  
vaccination 
CFT  
titres 
SAT  
titres 
0 1:0  1:0 
2 1:38  1:68 
4 1:16  1:33 
8 1:11  1:7 
15 1:5  1:0 
24 1:3  1:0 
 
The percentage of vaccinated animals positive to 
CFT, SAT, ELISA and RBPT are presented in Table 4. 
The CFT detected antibodies to Brucella in 100, 100, 71, 
0 and 0% of animals two, four, eight, 15, and 24 weeks 
after vaccination respectively compared to 100, 100, 100, 
100, 40%, in the ELISA. The SAT detected the lowest 
percentages (88, 67, 0, 0 and 0%) two, four, eight, 15 and 
24 weeks post vaccination. The RBPT and the ELISA 
gave similar results in this group. 
 
DISCUSSION 
 
Despite advances in molecular techniques, 
serology remains at the forefront of eradication and 
surveillance programmes for veterinary diseases and is 
an important tool in the fight against human brucellosis 
(McGiven, 2008). The immunological tests conducted on 
the three groups of goats vaccinated with Brucevac Rev.1 
vaccine indicated that no previous exposure to Brucella 
had taken place in these animals. 
In the light of the occurrence of brucellosis in sheep 
and goats in many countries (Gul and Khan, 2007), the 
most effective measure to reduce prevalence to a point 
where eradication by test-and-slaughter is feasible, is 
through an annual campaign to vaccinate adult sheep and 
 
Table 4: Percentages of seropositive animals (Group 3) to serological tests post vaccination subcutaneously 
with a reduced dose of live attenuated Brucella melitensis Rev.1 vaccine 
Weeks post 
vaccination 
Total 
number 
of animals 
Percentages of 
seropositive 
animals to 
RBPT 
Percentages of 
seropositive 
animals to 
CFT 
Percentages of 
seropositive 
animals to 
ELISA 
Percentages of 
seropositive 
animals to 
SAT 
0  10  0 0 0  0 
2  8  100 100 100  88 
4  9  100 100 100  67 
8 7  100  71  100 0 
15 8  100 0 100  0 
24 5  40 0 40  0 Pakistan Vet. J., 2009, 29(4): 149-153.   152
goats with a reduced dose or with a conjunctival dose of 
Rev 1 vaccine and vaccination of lamb and kids 3-8 
months old with a full dose of Rev.1 vaccine. Brucella 
melitensis strain Rev. 1 is recognised all over the world as 
the reference vaccine for protecting sheep and goats 
against B. melitensis infection (Verger, 1995; OIE, 2004). 
Vaccination will not only reduce the morbidity rate but 
will also reduce the perinatal mortality and the consequent 
economic losses caused by the disease.   
Vaccination with the reduced dose (1.54 x 10
5 
organisms) of Rev.1 vaccine produced at JOVAC induced 
a CFT response in all goats. The highest mean CFT 
antibody titre (1:38) was observed in vaccinated goats 
two weeks post vaccination, and then declined during the 
following weeks. This agreed with the work of Alton 
(1990), who observed that the CFT response began two to 
three days after vaccination, rising to a peak at two weeks 
and falling rapidly during the next month. Similarly, our 
results showed that all goats were seronegative to SAT by 
15 weeks post vaccination with a reduced dose of Rev.1 
vaccine, which is similar to the work of Alton (1990). The 
ELISA and the RBPT were the most sensitive serological 
tests for identifying animals vaccinated with the reduced 
dose of Rev.1 vaccine throughout the study period.  
All serological tests used in this study detected a 
higher percentage of vaccinated female kids with a full 
dose than they did in groups vaccinated with a reduced 
dose or with a conjunctival dose of the vaccine. Similarly, 
the peak mean CFT and SAT titres were recorded in 
animals vaccinated with a full dose of Rev.1 vaccine than 
animals vaccinated with either a reduced dose or with a 
conjunctival dose of Rev.1 vaccine. This result is in 
agreement with the findings of Aldomy (1992).   
Moreover, SAT titres in vaccinated animals with a full 
dose of Rev.1 vaccine persisted longer than in goats 
vaccinated with a reduced dose.  
The ELISA and the RBPT detected a higher 
percentage of vaccinated animals than the other 
serological tests 15 weeks after vaccination in all 
vaccinated animals with a reduced dose and with a 
conjunctival dose of the vaccine after 24 weeks, but the 
CFT, ELISA and the RBPT detected similar percentage 
(100%) of vaccinated animals with a full dose at two, 
four, eight and 15 weeks post vaccination. Sera collected 
from animals and tested by the CFT 15 weeks post 
vaccination with the full dose and conjunctival dose 
demonstrated that 100% of animals were seropositive, 
whereas 0% of animals vaccinated with the reduced dose 
were seropositive.  
The overall results indicated that ELISA (indirect 
ELISA test) and RBPT were by far the most sensitive 
serological tests to detect vaccinated animals, either with 
the full or the reduced dose or the conjuctival (eye drop) 
dose of Rev.1 vaccine when compared with CFT and 
SAT. Therefore, the ELISA and RBPT must be 
considered as screening tests and positive results by these 
tests in testing vaccinated animals should be confirmed 
By CFT. 
Peak mean SAT titres were observed 15 weeks post 
vaccination in goats vaccinated with a full dose, two 
weeks in goats vaccinated with a reduced dose and four 
weeks in animals vaccinated with a conjunctival dose. No 
conclusion could be made from the results of sera 
collected from vaccinated goats by the use of the SAT. 
The SAT failed to give a positive result in many goats in 
which antibody had been detected after natural exposure 
to vaccine antigen. These observations agree with Zowghi 
and Ebadi (1985) in Iran, who stated that the CFT proved 
to be an extremely reliable test for the diagnosis of 
brucellosis in animals especially where the results of SAT 
were negative which may occur in the incubation period 
or in chronic infection. 
The overall results suggest that 100% of animals 
vaccinated with a conjunctival dose of Brucevac 
vaccine became positive to CFT at two, four, eight and 
15 weeks post vaccination, and then the percentage of 
seropositive animals declined and became 20% at 24 
weeks post vaccination. The conjunctival route of 
vaccination significantly reduced the intensity and 
duration of the post vaccination serological response 
and made the use of this vaccine compatible with 
brucellosis eradication programmes, even when these 
are based on a test-and–slaughter policy.  
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